Future Bright for EBOS Despite Setbacks
Future Bright for EBOS Despite Setbacks
On Wednesday, EBOS reported a 7.2% increase in statutory net profit after tax to NZ$271.5 million. Revenue grew by nearly 8% to NZ$13.2 billion, and EBOS Group (ASX:EBO), the New Zealand-based healthcare and pet products company, is moving forward with renewed confidence after a successful year. Despite a failed attempt to acquire Greencross in late 2023, EBOS has reported record sales and profits for the year ending June 30.
新西蘭的醫療保健和寵物產品公司EBOS Group（ASX:EBO）在經歷了一個成功的年度後，充滿信心地邁進。儘管在2023年底未能成功收購Greencross，EBOS在截至6月30日的年度報告中報告了創紀錄的銷售額和利潤。
The company's statutory net profit increased due to strong sales, which reached a new high of NZ$13 billion. However, this will be the last time EBOS reports such a large figure, as its supply deal with Chemists Warehouse ended on June 30. While the loss of this wholesale business will have an impact, the company expects minimal growth in earnings for the current financial year.
由於強勁的銷售業績，公司的法定淨利潤增加，達到了NZ$13億的歷史新高。然而，這將是EBOS最後一次報告這樣龐大的數字，因爲其與Chemists Warehouse的供應協議於6月30日結束。儘管失去這項批發業務將產生影響，但公司預計本財年盈利增長率較低。
EBOS operates in two main retail channels: supermarkets for pet care products and chemists and wholesalers for healthcare. Its most well-known healthcare businesses are Terry White Chemists and Symbion. The company's attempt to acquire Greencross was motivated by the loss of sales revenue to Chemists Warehouse.
EBOS在兩個主要零售渠道運作：超市銷售寵物護理產品，藥房和批發商銷售醫療保健產品。公司最知名的醫療保健業務是Terry White Chemists和Symbion。EBOS收購Greencross的舉措是爲了彌補因Chemists Warehouse的銷售收入損失。
On Wednesday, EBOS reported a 7.2% increase in statutory net profit after tax to NZ$271.5 million. Revenue grew by nearly 8% to NZ$13.2 billion, and EBITDA increased by 6.5% to NZ$605.6 million. However, the company anticipates a decline in EBITDA due to the loss of the Chemists Warehouse supply deal.
EBOS在週三報告了法定稅後淨利潤增長7.2％至NZ$2,715萬元。收入增長近8％至NZ$13.2億，EBITDA增長6.5％至NZ$6,056萬元。然而，由於失去了與Chemists Warehouse的供應協議，公司預計EBITDA會下降。
The Christchurch-based company declared a final dividend of 61.5 NZ cents per share, bringing the total dividends to 118.5 NZ cents.
這家總部位於基督城的公司宣佈每股支付61.5新西蘭分的最終股息，使總股息達到118.5新西蘭分。
EBOS attributed its record sales to growth in its community pharmacy and institutional healthcare divisions. The company highlighted strategic investments, including its stake in Transmedic, the acquisition of Superior Pet Food, and smaller acquisitions in medical technology and consumables.
EBOS將其創紀錄的銷售額歸因於社區藥房和醫療機構的增長。公司強調了戰略性投資，包括其在Transmedic的股權，對Superior Pet Food的收購以及在醫療技術和消耗品領域的較小收購。
"The group's diversification is a key strength as we navigate challenging domestic economic conditions," said EBOS CEO John Cullity. "We have a strong pipeline of opportunities ahead as we continue to expand our operations outside New Zealand and Australia."
EBOS首席執行官John Cullity表示：「集團的多元化是我們在挑戰性的國內經濟環境中的一大優勢。我們面前有一條強勁的機會管道，我們將繼續擴大在新西蘭和澳洲以外地區的業務。」
A significant factor for EBOS is the ongoing merger of Chemists Warehouse and Sigma Healthcare. The ACCC is likely to require the merged group to divest certain assets, particularly in wholesale and chemist retail outlets. This could present opportunities for EBOS to expand its businesses in Australia, potentially offsetting the loss of revenue from the Chemists Warehouse supply arrangement.
對EBOS來說，Chemists Warehouse與Sigma Healthcare的持續合併是一個重要因素。澳大利亞競爭與消費者委員會（ACCC）可能要求合併集團出售特定資產，尤其是批發和藥房零售門店。這可能爲EBOS在澳大利亞擴大業務提供機會，從而可能抵消Chemists Warehouse供應安排帶來的收入損失。